Stem Cell Therapy in Limb Girdle Muscular Dystrophy

The Role of Cell Therapy in Modifying the Course of Limb Girdle Muscular Dystrophy- A Longitudinal 5-year Study

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02050776

Enrollment

Registered

2014-01-31

Start date

2008-12-31

Completion date

2013-12-31

Last updated

2018-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Limb Girdle Muscular Dystrophy

Brief summary

The purpose of this study was to study the effect of stem cell therapy on the course of the disease in patients with Limb Girdle Muscular Dystrophy.

Interventions

BIOLOGICALAutologous bone marrow mononuclear cell transplantation

bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

15 Years to 60 Years

Healthy volunteers

Inclusion criteria

* males and females * age group of 15 years and above * limb girdle muscular dystrophy diagnosed on the basis of clinical presentation * Electromyographic and Nerve Conduction velocity findings

Exclusion criteria

* presence of respiratory distress * presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus * malignancies * acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction \< 30% * pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
Functional Independence Measure	6 months

Secondary

Measure	Time frame
Manual Muscle Testing	6 months

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026